All of the shares are being offered by Avigen. Salomon Smith Barney Inc., CIBC World Markets Corp. and ING Barings LLC are managers of the underwriting syndicate that will offer the shares to the public. Avigen is a leader in the development of gene therapy products for the treatment of inherited diseases. Avigen is developing its proprietary adeno-associated virus vector technology, known as AAV vectors, to deliver DNA to patients that are suffering from genetic diseases.
AAV vectors are a relatively new system for gene therapy.